Acumen Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Acumen Pharmaceuticals expects to announce top-line results from its Phase 2 ALTITUDE-AD trial of Sabrina Tug in November 2026.
- The trial tests two doses of Sabrina Tug against placebo and was designed to detect a statistically significant difference on the primary efficacy endpoint after 18 months of treatment.
- The expected top-line dataset includes primary and key secondary efficacy outcomes, safety evaluations including adverse events and ARIA rates, and fluid and imaging biomarkers.
- Acumen reported third-quarter 2026 R&D expenses of $21.1 million, DNA expenses of $4.7 million, a loss from operations of $25.8 million, and a net loss of $25.4 million.
- The year-over-year decrease in R&D expenses was primarily due to lower manufacturing and materials costs and CRO costs associated with the ALTITUDE-AD clinical trial.
- Acumen ended the third quarter with approximately $79 million in cash and marketable securities.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Day, and welcome to the Acumen Pharmaceuticals third quarter 2026 conference call and webcast. At this time, all participants are in listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, you will need to press star 11 on your touchtone telephone. Please note this call may be recorded. I would like to turn the call over to Alex Braun, Head of Investor Relations. Please go ahead. Thanks, Michelle.
Good morning and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended September 30, 2026. With me today are Dan O'Connell, our Chief Executive Officer, and Matt Zuga, our CFO and Chief Business Officer. They all have brief prepared remarks, and then we will open the call for questions. Before we begin, we encourage listeners to go to the investor section of the Acumen website to find our press release issued this morning that we will discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans.
Please see slide 2 of our corporate presentation, our press release issued this morning, and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or any accompanying presentation as a result of new information or future results or developments. With that, I will turn the call over to Dan.
Great. Thanks, Alex. Good morning, everyone, and thanks for joining us today. In the third quarter, our team has been very busy readying for the top-line readout from our phase II ALTITUDE-AD trial investigating our lead product candidate, sabirnetug. If you have been following our company for some time, you are likely well aware that these results are highly anticipated. We are testing our central scientific thesis that arresting the harm done by synaptotoxic amyloid beta oligomers in the brain may offer a differentiated approach to treating Alzheimer's disease. Today, I am pleased to confirm that we expect to announce these phase II results this November. We are confident that we are fully evaluating the A-beta oligomer hypothesis with this study. ALTITUDE-AD is a large, well-powered phase II trial with clinically meaningful endpoints.
We are testing two doses of sabirnetug against placebo, carefully considered based on our phase I study in Alzheimer's patients, such that either dose may prove efficacious in the phase II. We have executed the study to a very high operational standard with rapid enrollment, close engagement with study sites and investigators, and high rollover into the open label extension of the study. As previously mentioned, we envision this study as part of a potential registration package and have conducted the study as such with a single confirmatory phase III anticipated following positive phase II results. As previously outlined, ALTITUDE-AD was designed to detect a statistically significant difference between sabirnetug and placebo on the primary efficacy endpoint, iADRS, following 18 months of treatment.
We expect the top-line data set to encompass primary endpoint results, key secondary outcomes, including the CDR-SB, safety evaluations covering adverse events and ARIA rates at a range of informative fluid and imaging biomarkers. We believe that sabirnetug has the potential to demonstrate a differentiated benefit to risk profile given its unique product attributes as a selective anti-A-beta oligomer IgG2 monoclonal. We look forward to sharing the data in November. We also continue to advance our enhanced brain delivery program, or EBD, for the treatment of Alzheimer's disease, representing the only program combining a validated blood-brain barrier penetrating technology with an A-beta oligomer selective therapeutic antibody. As a reminder, we are working on two candidates in the lead-up to an IND filing expected in mid-2027. One candidate, ACU301, is based on a bispecific antibody incorporating sabirnetug.
ACU401 incorporates a novel A-beta selective antibody with differentiated properties known as ACU234. We presented encouraging data at the AAIC meeting in July showing that after intravenous dosing, all tested EBD bispecific antibodies achieved multifold greater brain exposure than unmodified ACU234 alone. ACU401, in particular, achieved up to a 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions. The degree of brain penetration we observed in the cynomolgus monkeys, combined with the preserved soluble A-beta oligomer selectivity and a clean hematological profile, exceeded our expectations and give us confidence in the differentiated potential of our EBD program.
The imminent data readout for sabirnetug and the development of our next generation EBD candidates demonstrate both the robustness of our pipeline and our ability to deliver on key priorities, positioning us for an important period of value-creating milestones ahead, both near and longer term. Again, we look forward to updating you in November. With that, I'll turn the call over to Matt.
Thanks, Dan. As a reminder, our third quarter 2026 financial results are available in the press release we issued this morning and in our 10-Q we will file later today. We ended the third quarter with approximately $79 million in cash and marketable securities on our balance sheet, which is expected to support our current clinical and operational activities into early 2027. R&D expenses were $21.1 million in the third quarter. The decrease over the prior year was primarily due to reductions in manufacturing and materials costs, as well as CRO costs, which are both associated with our ALTITUDE-AD clinical trial. G&A expenses were $4.7 million in the third quarter, roughly flat to the same period in the prior year. This led to a loss from operations of $25.8 million and a net loss of $25.4 million in the third quarter.
We look forward to reporting on our phase II ALTITUDE-AD study next month and remain committed to maximizing the potential of our portfolio of A-beta oligomer-targeted antibodies to generate value for patients living with Alzheimer's disease, their caregivers, and our stakeholders. With that, we can open the call for Q&A.
Operator? Thank you. As a reminder, to ask a question, please press star 1 1.
If your question has been answered and you would like to remove yourself from the queue, press star 1 1 again. Our first question comes from Jason Zemansky with Bank of America. Your line is open. Good morning.
Congratulations on the progress. Looking forward to the results. This may seem like a random question now, but as we think about the evolving treatment paradigm, it looks like Biogen is now positioning LEQEMBI as a follow-on after donanemab clears plaque. The argument is that soluble species sort of keep driving disease after the plaque is gone. So it seems like a natural place for an oligomer selective antibody. How do you think about sabirnetug in addition to sort of a primary role, but as a maintenance after plaque clearance or in combination with a plaque clearer, and could anything in the ALTITUDE-AD data set inform that? Thanks so much. Thanks, Jason.
Great question. We have always been advocates for chronic dosing essentially while patients are stable within an early AD stage of disease, as we believe these soluble aggregates are present and persistent in driving disease pathology. It would be a logical extension to consider sabirnetug or an oligomer-selective antibody as a post-plaque clearance follow-on. In the primary mode, we are focused on the primary outcome for sabirnetug and ALTITUDE-AD with an 18-month primary using the iADRS. I think we will have the first clear evidence is really out of that phase II moving towards phase III, but the therapeutic rationale for sabirnetug as a follow-on would make sense to us as we sit here today.
Great. Thanks so much for the color.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
